- Aspirin use was associated with reduced risk of death in biliary tract cancer (BTC), and new users seemed to benefit most.
Why this matters
- Aspirin might slow metastasis by interfering with platelet activation.
- Retrospective analysis of UK’s Clinical Practice Research Datalink database (n=2934).
- Funding: NIH; National Cancer Institute.
- 23% of patients had gallbladder cancer (GBC), 53% had cholangiocarcinoma, 8% had ampulla of Vater cancer (AVC), and 16% were overlapping.
- 82% of patients died and the median survival was 5.8 (interquartile range, 2-15) months.
- 9% were using aspirin at baseline, and 12% initiated aspirin after diagnosis. 96% were prescribed a 75 mg dose.
- Aspirin users were more likely to be older, current statin users, and to use aspirin before their diagnosis. Heart disease and comorbidities were more common in aspirin users.
- There was an association between aspirin use and decreased mortality risk in:
- GBC: HR, 0.63; 95% CI, 0.48-0.83.
- cholangiocarcinoma: HR, 0.71; 95% CI, 0.60-0.85.
- AVC: HR, 0.44; 95% CI, 0.26-0.76.
- overlapping BTC: HR, 0.68; 95% CI, 0.50-0.92.
- In all categories, the survival benefit was higher in patients who had not used aspirin before diagnosis.
- Retrospective analysis.